Skip to main content
Erschienen in: The journal of nutrition, health & aging 10/2018

19.11.2018

Use of ACE-inhibitors and Quality of Life in an Older Population

verfasst von: A. Laudisio, Silvia Giovannini, P. Finamore, A. Gemma, R. Bernabei, R. A. Incalzi, G. Zuccalà

Erschienen in: The journal of nutrition, health & aging | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Improved ability to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQoL) in older adults. Hypertension and heart failure have been associated with decreased HRQoL.

Hypothesis

The aim of this study was to assess the association between health-related quality of life and use of angiotensin converting enzyme inhibitors in unselected community-dwelling elderly.

Methods

We analyzed data of all 387 subjects aged 75+ living in a rural Italian town, without exclusion criteria. HRQoL was assessed using the Health Utility Index Mark 3, which allows formal cost-effectiveness calculations. The association of the HRQoL score with use of ACE-I was analyzed by multivariable linear and logistic regression.

Results

The median HUI3 score was 0.31, and 186 participants (48%) reported a score above the median value. Use of ACE-I was reported by 34 (9%) participants, and confirmed by general practitioners. Use of these agents was associated with significantly better HRQoL (B=.16, 95% CI=.02 -.30; P=.025). Also, use of ACE-I was associated with increased probability of better HRQoL in logistic regression (OR=2.83; 95% CI=1.03 - 7.78; P=.044) after adjusting. No associations were found between the HRQoL score and use of calcium antagonists or beta-blockers.

Conclusions

Use of ACE-I, but not of other antihypertensives, is associated with better HRQoL among community-dwelling older adults. ACE-inhibitors might therefore present with the best cost-effectiveness ratio for the treatment of older populations.
Literatur
1.
Zurück zum Zitat Rumsfeld JS, Alexander KP, Goff DC, et al. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation. 2013;127(22):2233–2249. doi:10.1161/CIR.0b013e3182949a2e.CrossRefPubMed Rumsfeld JS, Alexander KP, Goff DC, et al. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation. 2013;127(22):2233–2249. doi:10.1161/CIR.0b013e3182949a2e.CrossRefPubMed
2.
Zurück zum Zitat Waller DG. Effect of drug treatment on quality of life in mild to moderate heart failure. Drug Saf. 1991;6(4):241–246.CrossRefPubMed Waller DG. Effect of drug treatment on quality of life in mild to moderate heart failure. Drug Saf. 1991;6(4):241–246.CrossRefPubMed
3.
Zurück zum Zitat Hollenberg NK, Testa M, Williams GH. Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension. Drug Saf. 1991;6(2):83–93.PubMed Hollenberg NK, Testa M, Williams GH. Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension. Drug Saf. 1991;6(2):83–93.PubMed
4.
Zurück zum Zitat Degl’Innocenti A, Elmfeldt D, Hofman A, et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens. 2004;18(4):239–245. doi:10.1038/sj.jhh.1001657.CrossRefPubMed Degl’Innocenti A, Elmfeldt D, Hofman A, et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens. 2004;18(4):239–245. doi:10.1038/sj.jhh.1001657.CrossRefPubMed
5.
Zurück zum Zitat Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther. 2003;17(2):133–139.CrossRefPubMed Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther. 2003;17(2):133–139.CrossRefPubMed
6.
Zurück zum Zitat Chien K-L, Huang P-J, Chen M-F, Chiang F-T, Lai L-P, Lee Y-T. Assessment of quality of life in a double-blind, randomized clinical trial of imidapril and captopril for hypertensive Chinese in Taiwan. Cardiovasc Drugs Ther. 2002;16(3):221–226.CrossRefPubMed Chien K-L, Huang P-J, Chen M-F, Chiang F-T, Lai L-P, Lee Y-T. Assessment of quality of life in a double-blind, randomized clinical trial of imidapril and captopril for hypertensive Chinese in Taiwan. Cardiovasc Drugs Ther. 2002;16(3):221–226.CrossRefPubMed
7.
Zurück zum Zitat Laudisio A, Marzetti E, Antonica L, et al. Masticatory dysfunction is associated with osteoporosis in older men. J Clin Periodontol. 2007;34(11):964–968. doi:10.1111/j.1600-051X.2007.01142.x.CrossRefPubMed Laudisio A, Marzetti E, Antonica L, et al. Masticatory dysfunction is associated with osteoporosis in older men. J Clin Periodontol. 2007;34(11):964–968. doi:10.1111/j.1600-051X.2007.01142.x.CrossRefPubMed
8.
Zurück zum Zitat Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–128.CrossRefPubMed Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–128.CrossRefPubMed
9.
Zurück zum Zitat WHO | ATC/DDD Toolkit. WHO. http://www.who.int/medicines/regulation/medicines-safety/toolkit/en/. Accessed October 11, 2017. WHO | ATC/DDD Toolkit. WHO. http://​www.​who.​int/​medicines/​regulation/​medicines-safety/​toolkit/​en/​.​ Accessed October 11, 2017.
10.
Zurück zum Zitat Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial and function. JAMA. 1963;185:914–919.PubMed Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial and function. JAMA. 1963;185:914–919.PubMed
11.
Zurück zum Zitat Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49.CrossRefPubMed Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49.CrossRefPubMed
12.
Zurück zum Zitat Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972;1(4):233–238.CrossRefPubMed Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972;1(4):233–238.CrossRefPubMed
13.
Zurück zum Zitat WHO | International Classification of Diseases. WHO. http://www.who.int/classifications/icd/en/. Accessed October 11, 2017. WHO | International Classification of Diseases. WHO. http://​www.​who.​int/​classifications/​icd/​en/​.​ Accessed October 11, 2017.
14.
Zurück zum Zitat Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29(2):179–188. doi:10.1097/HJH.0b013e328340d76f.CrossRefPubMed Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29(2):179–188. doi:10.1097/HJH.0b013e328340d76f.CrossRefPubMed
15.
Zurück zum Zitat Leonetti G, Comerio G, Cuspidi C. Evaluating quality of life in hypertensive patients. J Cardiovasc Pharmacol. 1994;23 Suppl 5:S54–58.CrossRefPubMed Leonetti G, Comerio G, Cuspidi C. Evaluating quality of life in hypertensive patients. J Cardiovasc Pharmacol. 1994;23 Suppl 5:S54–58.CrossRefPubMed
16.
Zurück zum Zitat Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314(26):1657–1664. doi:10.1056/NEJM198606263142602.CrossRefPubMed Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314(26):1657–1664. doi:10.1056/NEJM198606263142602.CrossRefPubMed
17.
Zurück zum Zitat Boal AH, Smith DJ, McCallum L, et al. Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertens Dallas Tex 1979. 2016;68(5):1132–1138. doi:10.1161/HYPERTENSIONAHA.116.08188. Boal AH, Smith DJ, McCallum L, et al. Monotherapy With Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertens Dallas Tex 1979. 2016;68(5):1132–1138. doi:10.1161/HYPERTENSIONAHA.116.08188.
18.
Zurück zum Zitat Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer’s disease? An overview of research evidence in the elderly patient population. J Postgrad Med. 2016;62(4):242–248. doi:10.4103/0022-3859.188553.CrossRefPubMedPubMedCentral Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer’s disease? An overview of research evidence in the elderly patient population. J Postgrad Med. 2016;62(4):242–248. doi:10.4103/0022-3859.188553.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Brownstein DJ, Salagre E, Köhler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. July 2017:4867417721654. doi:10.1177/0004867417721654. Brownstein DJ, Salagre E, Köhler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. July 2017:4867417721654. doi:10.1177/0004867417721654.
20.
Zurück zum Zitat Zuccalà G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J. 2005;26(3):226–233. doi:10.1093/eurheartj/ehi058.CrossRefPubMed Zuccalà G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J. 2005;26(3):226–233. doi:10.1093/eurheartj/ehi058.CrossRefPubMed
21.
Zurück zum Zitat Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-a mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62(1):145–157. doi:10.1002/glia.22595.CrossRefPubMed Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-a mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62(1):145–157. doi:10.1002/glia.22595.CrossRefPubMed
22.
Zurück zum Zitat Laudisio A, Lo Monaco MR, Silveri MC, et al. Use of ACE-inhibitors and falls in patients with Parkinson’s disease. Gait Posture. 2017;54:39–44. doi:10.1016/j. gaitpost.2017.02.007.CrossRefPubMed Laudisio A, Lo Monaco MR, Silveri MC, et al. Use of ACE-inhibitors and falls in patients with Parkinson’s disease. Gait Posture. 2017;54:39–44. doi:10.1016/j. gaitpost.2017.02.007.CrossRefPubMed
23.
Metadaten
Titel
Use of ACE-inhibitors and Quality of Life in an Older Population
verfasst von
A. Laudisio
Silvia Giovannini
P. Finamore
A. Gemma
R. Bernabei
R. A. Incalzi
G. Zuccalà
Publikationsdatum
19.11.2018
Verlag
Springer Paris
Erschienen in
The journal of nutrition, health & aging / Ausgabe 10/2018
Print ISSN: 1279-7707
Elektronische ISSN: 1760-4788
DOI
https://doi.org/10.1007/s12603-018-1135-0

Weitere Artikel der Ausgabe 10/2018

The journal of nutrition, health & aging 10/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.